David A. Siegel Biotechnology

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
MGNX Macrogenics Inc	$224M	$3.43 Million 0.01% of portfolio	1,044,004	Q3 2024 Reduced 9.33%
FATE Fate Therapeutics Inc	$307M	$3.25 Million 0.01% of portfolio	927,240	Q3 2024 Reduced 39.14%
HRMY Harmony Biosciences Holdings, Inc.	$2.12B	$3.24 Million 0.01% of portfolio	81,200	Q3 2024 Reduced 12.41%
RXRX Recursion Pharmaceuticals, Inc.	$1.15B	$3.23 Million 0.01% of portfolio	489,900	Q3 2024 Added 12.41%
AVXL Anavex Life Sciences Corp.	$704M	$2.8 Million 0.01% of portfolio	493,500	Q3 2024 Reduced 22.04%
CRSP Crispr Therapeutics Ag	$3.99B	$2.65 Million 0.01% of portfolio	56,400	Q3 2024 New
ENTA Enanta Pharmaceuticals Inc	$183M	$2.42 Million 0.01% of portfolio	233,000	Q3 2024 Added 0.09%
DYN Dyne Therapeutics, Inc.	$1.61B	$2.18 Million 0.01% of portfolio	60,700	Q3 2024 Reduced 51.05%
ERAS Erasca, Inc.	$357M	$2.17 Million 0.01% of portfolio	793,200	Q3 2024 Reduced 5.94%
REPL Replimune Group, Inc.	$693M	$2.06 Million 0.0% of portfolio	188,400	Q3 2024 Reduced 10.16%
CRBU Caribou Biosciences, Inc.	$134M	$2.06 Million 0.0% of portfolio	1,054,100	Q3 2024 Added 1.78%
STRO Sutro Biopharma, Inc.	$140M	$2.04 Million 0.0% of portfolio	590,900	Q3 2024 Reduced 13.93%
AVIR Atea Pharmaceuticals, Inc.	$288M	$1.95 Million 0.0% of portfolio	582,400	Q3 2024 Reduced 4.87%
NKTR Nektar Therapeutics	$212M	$1.95 Million 0.0% of portfolio	1,500,242	Q3 2024 Reduced 18.28%
ARWR Arrowhead Pharmaceuticals, Inc.	$2.77B	$1.94 Million 0.0% of portfolio	100,000	Q3 2024 Reduced 2.06%
KURA Kura Oncology, Inc.	$747M	$1.91 Million 0.0% of portfolio	97,999	Q3 2024 Reduced 14.56%
LQDA Liquidia Corp	$748M	$1.87 Million 0.0% of portfolio	187,400	Q3 2024 Reduced 26.48%
ALEC Alector, Inc.	$211M	$1.84 Million 0.0% of portfolio	394,900	Q3 2024 Reduced 17.68%
PLRX Pliant Therapeutics, Inc.	$659M	$1.77 Million 0.0% of portfolio	157,800	Q3 2024 Reduced 16.82%
MDXG Mimedx Group, Inc.	$1.07B	$1.76 Million 0.0% of portfolio	297,700	Q3 2024 Reduced 44.22%
ARQT Arcutis Biotherapeutics, Inc.	$705M	$1.7 Million 0.0% of portfolio	182,800	Q3 2024 Reduced 62.59%
COGT Cogent Biosciences, Inc.	$630M	$1.69 Million 0.0% of portfolio	156,090	Q3 2024 Reduced 10.18%
DSGN Design Therapeutics, Inc.	$333M	$1.64 Million 0.0% of portfolio	304,900	Q3 2024 Reduced 23.79%
HRTX Heron Therapeutics, Inc.	$138M	$1.61 Million 0.0% of portfolio	811,371	Q3 2024 Added 614.86%
DAWN Day One Biopharmaceuticals, Inc.	$1.01B	$1.6 Million 0.0% of portfolio	115,100	Q3 2024 Added 36.54%
LEGN Legend Biotech Corp	$7.04B	$1.59 Million 0.0% of portfolio	32,600	Q3 2024 New
SLN Silence Therapeutics PLC	$275M	$1.52 Million 0.0% of portfolio	83,300	Q3 2024 Added 9.32%
TECH Bio Techne Corp	$2.96B	$1.5 Million 0.0% of portfolio	18,800	Q3 2024 Reduced 21.99%
CDXS Codexis, Inc.	$301M	$1.49 Million 0.0% of portfolio	485,100	Q3 2024 Reduced 23.3%
RAPT Rapt Therapeutics, Inc.	$36.5M	$1.42 Million 0.0% of portfolio	705,000	Q3 2024 Added 0.95%
RVMD Revolution Medicines, Inc.	$5.14B	$1.4 Million 0.0% of portfolio	30,866	Q3 2024 Reduced 32.93%
FULC Fulcrum Therapeutics, Inc.	$206M	$1.36 Million 0.0% of portfolio	382,200	Q3 2024 Reduced 32.17%
ARDX Ardelyx, Inc.	$888M	$1.33 Million 0.0% of portfolio	193,600	Q3 2024 Reduced 56.37%
EYPT Eye Point Pharmaceuticals, Inc.	$308M	$1.33 Million 0.0% of portfolio	166,500	Q3 2024 Reduced 5.56%
CABA Cabaletta Bio, Inc.	$110M	$1.33 Million 0.0% of portfolio	281,200	Q3 2024 Added 287.86%
NRIX Nurix Therapeutics, Inc.	$1B	$1.33 Million 0.0% of portfolio	59,100	Q3 2024 Reduced 33.97%
AMRN Amarin Corp Plcuk	$198M	$1.24 Million 0.0% of portfolio	1,976,000	Q3 2024 Reduced 23.7%
SVRA Savara Inc	$396M	$1.23 Million 0.0% of portfolio	289,915	Q3 2024 Reduced 28.28%
NUVB Nuvation Bio Inc.	$628M	$1.23 Million 0.0% of portfolio	533,900	Q3 2024 Reduced 28.41%
EWTX Edgewise Therapeutics, Inc.	$2.03B	$1.21 Million 0.0% of portfolio	45,400	Q3 2024 Reduced 52.71%
OLMA Olema Pharmaceuticals, Inc.	$409M	$1.21 Million 0.0% of portfolio	101,200	Q3 2024 Reduced 21.85%
ETNB 89bio, Inc.	$422M	$1.21 Million 0.0% of portfolio	163,200	Q3 2024 Reduced 24.72%
BMEA Biomea Fusion, Inc.	$206M	$1.19 Million 0.0% of portfolio	117,600	Q3 2024 Added 6.23%
ABOS Acumen Pharmaceuticals, Inc.	$91.5M	$1.16 Million 0.0% of portfolio	469,100	Q3 2024 Added 19.64%
AUTL Autolus Therapeutics PLC	$297M	$1.15 Million 0.0% of portfolio	318,000	Q3 2024 Added 23.88%
CRNX Crinetics Pharmaceuticals, Inc.	$3.07B	$1.14 Million 0.0% of portfolio	22,400	Q3 2024 Reduced 33.33%
ALDX Aldeyra Therapeutics, Inc.	$288M	$1.13 Million 0.0% of portfolio	209,300	Q3 2024 Reduced 26.02%
PMVP Pmv Pharmaceuticals, Inc.	$73M	$1.12 Million 0.0% of portfolio	751,200	Q3 2024 Added 52.22%
YMAB Y M Abs Therapeutics, Inc.	$519M	$1.12 Million 0.0% of portfolio	85,000	Q3 2024 Reduced 13.0%
KZR Kezar Life Sciences, Inc.	$506M	$1.08 Million 0.0% of portfolio	1,402,900	Q3 2024 Added 13.36%

Shares Options

David A. Siegel

David A. Siegel is the co-founder and CEO of Two Sigma Advisers, a successful investment firm that uses technology and data-driven approaches to investing. Siegel is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track David A. Siegel's portfolio

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account